{
  "documents": [
    {
      "id": "cluster_40_doc1",
      "content": "Claim submitted for Russell Kowalski (PR-8892-346) for specialized infusion therapy at Desert Sage Neurology. Prior authorization required for ocrelizumab treatments administered bi-annually. Provider Dr. Elena Marquez noted concurrent fibromyalgia management affecting treatment schedule.",
      "metadata": {
        "format": "claim_form"
      }
    },
    {
      "id": "cluster_40_doc2",
      "content": "Patient PR-8892-346 chart shows worsening MS symptoms requiring adjusted medication dosages. Birthdate 1985-03-14. Current regimen includes pregabalin for fibromyalgia pain. Next infusion scheduled Q2 2024. Resides at 4352 Saguaro Vista, Phoenix.",
      "metadata": {
        "format": "medical_record"
      }
    },
    {
      "id": "cluster_40_doc3",
      "content": "Memo to adjust Phoenix-area policies: Effective April 2023, all infusion therapies for dual-diagnosis patients require additional outcome documentation. Impacts 14 current cases including patient russellk@phoenixmail.com.",
      "metadata": {
        "format": "insurance_memo"
      }
    },
    {
      "id": "cluster_40_doc4",
      "content": "Provider report from Desert Sage Neurology details exceptional-response case combining ocrelizumab with cognitive behavioral therapy for MS patient with fibromyalgia. Significant functional improvement in ADL scores over 12-month period.",
      "metadata": {
        "format": "provider_report"
      }
    },
    {
      "id": "cluster_40_doc5",
      "content": "12-month Phoenix observational study shows transportation barriers delay 38% of infusion appointments for patients requiring combination neurological/rheumatological care. Procrastination linked to 22% complication rate increase.",
      "metadata": {
        "format": "research_note"
      }
    }
  ],
  "metadata": {
    "category": "cluster",
    "cluster_id": "cluster_40",
    "cluster_risk": "HIGH",
    "content_summary": "Multiple sclerosis and fibromyalgia treatment journey with infusion therapy challenges in Phoenix",
    "person": {
      "entities": [
        [
          "Russell Kowalski",
          "NAME"
        ],
        [
          "russellk@phoenixmail.com",
          "EMAIL"
        ],
        [
          "PR-8892-346",
          "PATIENT_ID"
        ],
        [
          "1985-03-14",
          "BIRTHDATE"
        ],
        [
          "4352 Saguaro Vista, Phoenix",
          "ADDRESS"
        ],
        [
          "multiple sclerosis",
          "MEDICAL_CONDITION"
        ],
        [
          "fibromyalgia",
          "MEDICAL_CONDITION"
        ],
        [
          "Dr. Elena Marquez",
          "PROVIDER"
        ],
        [
          "Desert Sage Neurology",
          "PROVIDER"
        ],
        [
          "pregabalin",
          "TREATMENT"
        ],
        [
          "ocrelizumab",
          "TREATMENT"
        ],
        [
          "cognitive behavioral therapy",
          "TREATMENT"
        ],
        [
          "Q2 2024",
          "EVENT_DATE"
        ],
        [
          "April 2023",
          "EVENT_DATE"
        ],
        [
          "12-month period",
          "UNIQUE_FACT"
        ]
      ]
    },
    "questions": [
      {
        "q": "What infusion schedule did Russell Kowalski follow for multiple sclerosis at Desert Sage Neurology?",
        "a": "Bi-annual ocrelizumab treatments with Q2 2024 next scheduled infusion.",
        "sources": [
          "cluster_40_doc1"
        ],
        "type": "specific"
      },
      {
        "q": "Which policy update in April 2023 impacted prior authorization for infusion therapies?",
        "a": "Additional outcome documentation required for dual-diagnosis infusion patients.",
        "sources": [
          "cluster_40_doc3"
        ],
        "type": "general"
      },
      {
        "q": "Which two combination therapies were prescribed to patient PR-8892-346 for fibromyalgia and MS in 2023?",
        "a": "Ocrelizumab infusions with pregabalin and cognitive behavioral therapy.",
        "sources": [
          "cluster_40_doc2",
          "cluster_40_doc4"
        ],
        "type": "specific"
      },
      {
        "q": "What policy and transportation barriers affected Phoenix-area patients requiring dual-condition specialty infusions?",
        "a": "Policy requires extra documentation; transportation delays affect 38% appointments.",
        "sources": [
          "cluster_40_doc3",
          "cluster_40_doc5"
        ],
        "type": "general"
      }
    ]
  }
}